Skip to main content

Table 1 Characteristics of the studies included in the meta-analysis

From: Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis

Trial name

First author, year

Phase

Masking

Study type

NCT number

QoL measure

ECOG PS

Treatment arms

Follow-up, week

KEYNOTE-010 [14]

Barlesi F., 2019

II/III

Open label

RCT

NCT01905657

EQ-5D-3L, EORTC QLQ-C30

EORTCQLQ-LC13

0–1

Pembrolizumab 2 mg/kg Q3W, pembrolizumab 10 mg/kg Q3W

Docetaxel 75 mg/m2 Q3W

12

CheckMate 057 [15]

Reck M., 2018

III

Open label

RCT

NCT01673867

LCSS, EQ-5D 3L

0–1

Nivolumab 3 mg/kg Q2W

Docetaxel 75 mg/m2 Q3W

66

KEYNOTE-024 [16]

Brahme J. R., 2017

III

Open label

RCT

NCT02142738

EORTC QLQ-C30

EORTC QLQ-LC13, EQ-5D-3L

0–1

Pembrolizumab 200 mg Q3W

Five platinum-based chemotherapy regimens Q3W: carboplatin + pemetrexed (500 mg/m2), cisplatin (75 mg/m2) + pemetrexed (500 mg/m2), carboplatin + gemcitabine (1250 mg/m2), cisplatin (75 mg/m2) + gemcitabine (1250 mg/m2), or carboplatin + paclitaxel (200 mg/m2)

15

OAK [17]

Bordoni R., 2018

III

Open label

RCT

NCT02008227

EORTCQLQ-C30

EORTC QLQ-LC13.

0–1

Atezolizumab 1200 mg Q3W

Docetaxel 75 mg/m2 Q3W

15

CheckMate 017 [18]

Reck M., 2017

III

Open label

RCT

NCT01642004

LCSS, EQ-5D

0–1

Nivolumab 3 mg/kg Q2W

Docetaxel 75 mg/m2 Q3W

60

KEYNOTE-407 [19]

Mazieres J., 2018

III

Double blind

RCT

NCT02775435

EORTC QLQ-C30, EORTC

QLQ-LC13, EQ-5D-3L

0–1

Pembro 200 mg Q3W

Pbo Q3W + carboplatin AUC 6 and paclitaxel 200 mg/m2 Q3W or nab-paclitaxel 100 mg/m2 QW

18

PACIFIC [20]

Hui R., 2019

III

Double blind

RCT

NCT02125461

EORTC QLQ-C30

EORTC

QLQ-LC13, EQ-5D

0–1

Durvalumab 10 mg/kg Q2W

Matching placebo 1−42 days after chemoradiotherapy

48

EVIDENS [21]

Pero l. M., 2019

N/A

Double blind

RCT

NCT03382496

EQ-5D-3L

0–1

Nivolumab

NA

36

KEYNOTE-189 [22]

Garassino M. C., 2020

III

Double blind

RCT

NCT02578680

EORTC QLQ-C30

EORTC QLQ-LC13

0–1

Pembrolizumab (200 mg) or saline placebo Q3W

Pemetrexed (500 mg/m2) with carboplatin (5 mg/mL per min) or cisplatin (75 mg/m2, investigator’s choice) Q3W for four cycles, followed by pemetrexed maintenance therapy Q3W

21

MYSTIC (D/D + T)

[23]

Garon E. B., 2021

III

Open label

RCT

NCT02453282

EORTC QLQ-C30

EORTC QLQ-LC13

0–1

Durvalumab 20 mg/kg Q4W, durvalumab 20 mg/kg Q4W plus tremelimumab 1 mg/kg Q4W

Investigator’s choice of platinum-based doublet chemotherapy (four to six cycles)

24